{"title": "Novavax COVID-19 Vaccine, Adjuvanted", "author": "Center; Research", "url": "https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted", "hostname": "fda.gov", "description": "Novavax COVID-19 Vaccine, Adjuvanted", "sitename": "FDA", "date": "2023-06-06", "cleaned_text": "Adjuvanted is available under emergency use authorization (EUA) to prevent COVID-19 in individuals 12 years of age and older. The vaccine is authorized for emergency use to provide: - A two-dose primary series to individuals 12 years of age and older. - A first booster dose to the following individuals at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine: - Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate. - Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine. Novavax COVID-19 Vaccine, Adjuvanted contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual. The spike protein in this vaccine is produced in insect cells; the Matrix M-adjuvant contains saponin extracts from the bark of the Soapbark tree that is native to Chile. Fact Sheets (English) |Information||Last Updated| | |[Fact Sheet for Recipients and Caregivers](/media/159898/download?attachment) Regulatory Information (Emergency Use Authorization) |Information||Date| | |[Decision Memo Register Notices |Title||Date| | | Translations of the Fact Sheet for Recipients and Caregivers | | (October 19, 2022) [ ](/media/161223/download?attachment) (October "}